Biotech Values

[biocqr]

CLDN > Is the statement below any cause for optimism?

Still, in what Zeiher called "the most important message of this pilot trial," there was evidence of a dose-response effect for two parameters that reflect ventricular remodeling—specifically, natriuretic peptide levels, which rose substantially less over six months in the SERCA2a groups than in the placebo group (they didn't rise at all in the high-dose group), and LV end-systolic volume, which rose sharply in the placebo group and declined in the high-dose SERCA2a group.

http://www.medscape.com/viewarticle/790633#vp_2